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Disadvantaged populations across the globe exhibit a disproportionate burden of chronic kidney disease (CKD) because of
diﬀerences in CKD occurrence and outcomes. Although many CKD risk factors can be managed and modiﬁed to optimize clinical
outcomes, the prevailing socioeconomic and cultural factors in disadvantaged populations, more often than not, militate against
optimum clinical outcomes. In addition, disadvantaged populations exhibit a broader spectrum of CKD risk factors and may be
genetically predisposed to an earlier onset and a more rapid progression of chronic kidney disease. A basic understanding of the
vulnerabilities of the disadvantaged populations will facilitate the adaptation and adoption of the kidney disease treatment and
prevention guidelines for these vulnerable populations. The purpose of this paper is to examine recent discoveries and data on
CKD occurrence and outcomes in disadvantaged populations and explore strategies for the prevention and treatment of CKD in
these populations based on the established guidelines.
1. Background andEpidemiology
The global prevalence of chronic kidney disease (CKD) is in-
creasing and creating enormous socioeconomic burdens for
patients, families, society, and the health care system across
theglobe.DatafromthethirdNationalHealthandNutrition
Examination Survey (NHANES 1999–2004) suggest that
a b o u t1o u to f8a d u l tA m e r i c a n se x h i b i te v i d e n c eo f
CKD [1]. Comparable estimates have been reported in
Asia [2], Australia [3], and across Europe [4–6]. The lack
of national registries and limited representative national
surveys in developing countries make the estimation of the
burden of CKD in these countries diﬃcult. However, the
risk factors for CKD are known to be just as prevalent in
many developing countries as in the developed countries.
Therefore, the burden of CKD in those developing countries
may be comparable to those of the developed countries.
In addition, developing countries exhibit a disproportionate
burden of infectious and environmental factors that broaden
the spectrum of CKD risk factors and is apt to increase CKD
burden. A greater understanding of CKD onset and progres-
sion among racial/ethnic minorities and socioeconomically
disadvantaged persons in the US may provide insights into
CKD burdens in similar populations globally.
The Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines by the National Kidney Foundation in
2002deﬁnedCKDasfunctionalandstructuralabnormalities
of the kidneys that persist for more than three months. This
widely publicized and generally accepted guidelines in-
cluded the presence of markers of kidney damage such as
albuminuria in the deﬁnition of CKD and established ﬁve
progressive stages based on a sustained reduction in the
estimated glomerular ﬁltration rate (eGFR) with speciﬁc
evaluation and treatment recommendations [7]. (Table 1)
ThisexpandeddeﬁnitionofCKDallowsfortheidentiﬁcation
of CKD in its earliest stages when the eGFR might still be
well within the normal limits and is critical to early detection
and treatment of CKD.
There is a dearth of population-based prevalence data on
the diﬀerent stages of CKD across the globe. In the United2 International Journal of Nephrology
Table 1: Stages of chronic kidney disease.
Stage Description eGFR (mL/min/1.73m2) Prevalence estimates,
1988–1994
Prevalence estimates,
1999–2004
1
Slight kidney damage
with normal or
increased ﬁltration
More than 90 1.7% (95% CI 1.3%–2.2%) 1.8% (95% CI 1.4%–2.3%)
2 Mild decrease in kidney
function 60–89 2.7% (95% CI 2.2%–3.2%) 3.2% (95% CI 2.6%–3.9%)
3 Moderate decrease in
kidney function 30–59 5.4% (95% CI 4.9%–6.0%) 7.7% (95% CI 7.0%–8.4%)
4 Severe decrease in
kidney function 15–29 0.21% (95% CI
0.15%–0.27%)
0.35% (95% CI
0.25%–0.45%)
Data from [1].
States (US), the National Health and Examination Survey
estimated that the prevalence of CKD stages from 1 to 4
increased from 10.0% (95% conﬁdence interval [CI], 9.2%–
10.9%) in 1988–1994 to 13.1% (95% CI, 12.0%–14.1%) in
1999–2004 with a prevalence ratio of 1.3 (95% CI, 1.2–
1.4). The speciﬁc prevalence estimates for CKD stages 1
to 4 in 1988–1994 and 1999–2004 are as shown in Table 1
[1]. Although the CKD prevalence data across Europe are
comparable to those of the US, the progression of CKD to
treated end-stage renal disease (ESRD) is generally slower in
Europe than in the USA [8].
2. Risk Factors and Rate of Progression
The increasing prevalence of diabetes across the nations
is the greatest risk factor for CKD in the world. It has
been estimated that there would be 366 million adults with
diabetes worldwide by the year 2030 [9]. The prevalence
of diabetes in developing countries is rapidly approaching
that of developed countries. In Mexico, the prevalence
o fd i a b e t e si sa sh i g ha s2 5 %a m o n g2 5t o4 0 - y e a r - o l d
Mexicans [10]. The rising rates of diabetes in developing
countries will engender a disproportionate burden of CKD
in these disadvantaged populations. Diabetic nephropathy
is becoming increasingly recognized as the leading cause of
CKD in both the developed and many developing countries.
In fact, diabetic nephropathy accounts for 65% of the ESRD
in Puerto Rico [11] and is a common cause of ESRD in many
countries in Africa and the Middle East [12].
The onset and progression of CKD vary from one
etiologytoanotherandfrompatienttopatient,evenwiththe
same etiology. Regardless of the etiology, established CKD
can accelerate its own course by inducing cardiovascular
(CV) disease and metabolic complications. The risk of this
CV disease and hence the rate of CKD progression is gener-
ally higher at stages 3–5 than at earlier stages of CKD [13].
The presence of multiple risk factors such as hypertension
and lipid disorders is also apt to promote an earlier onset
and a more rapid progression of CKD, and may explain
the fact that hypertension and diabetes account for two-
thirds of the ESRD in the United States [14]. Disadvantaged
populations, particularly in developing countries, frequently
exhibit multiple risk factors for CKD and harbor nontra-
ditional risk factors such as schistosomiasis, tuberculosis
and amyloidosis [15]. Environmental pollution, pesticides,
analgesic abuse, herbal medications, and unregulated food
additives also contribute to the disproportionate burden of
CKD in many disadvantaged populations worldwide [16].
The progression of CKD to ESRD has been reported to
be more rapid in the USA than in Europe. Within the USA
however, the prevalence of early CKD is comparable across
racial/ethnic categories but the progression of CKD to ESRD
is far more rapid among minority populations, with ESRD
rates nearly 4-fold higher among African Americans in com-
parisontoUSWhites,despitesimilarprevalenceratesofearly
CKD [17]. The rapid progression of CKD to ESRD among
minority populations in the USA is largely attributable
to higher prevalence and greater severity of diabetes and
hypertension, lower socioeconomic status, lesser access to
care, excess exposure to environmental toxins, and other
factors [18]. Compared with Whites, African Americans
have much higher rates and earlier onset of diabetes and
hypertension and exhibit greater rates of diabetic and hyper-
tensive complications such as CKD, stroke, and heart disease
[19]. In spite of the eﬀectiveness of the control of serum
glucose and blood pressure levels to mitigate the progression
of diabetic nephropathy [20], the overall blood pressure
control remains unacceptably low ranging from 50% in the
USA [21] to about 64% in Canada [22]. The pathologic
synergy of hypertension with diabetes as well as the higher
rate of hypertension and the lower rate of blood pressure
control may contribute to the more rapid progression of
CKD to ESRD amongst African Americans. Given the high
prevalenceofhypertension,particularattentiontoitscontrol
is paramount for preventing CKD initiation and progression
(Figure 1).
Although the pathophysiologic basis for the variation
in the progression of CKD to ESRD across populations is
probably multifactorial and currently poorly understood,
it is becoming increasingly apparent that gene-based dif-
ferences in disease proﬁle [23] may contribute to the
disproportionate burden of CKD across populations. A few
rare kidney diseases exhibit monogenic abnormalities with
Mendelian patterns of inheritance but genetic variations are
becoming increasingly associated with an increased risk of
developing common kidney diseases in population-based
genetic studies. Genome-wide admixture mapping studies
have recently revealed variations in the regions of MYH9 andInternational Journal of Nephrology 3
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Figure 1: Algorithm for a comprehensive approach to hypertension control in disadvantaged persons with chronic kidney disease (CKD).
SBP; systolic blood pressure; DBP; diastolic blood pressure; BB; beta blocker; ACEI; angiotensin converting enzyme inhibitor; ARB;
angiotensin receptor blocker; CV; cardiovascular; CCB; calcium channel blocker; eGFR; estimated glomerular ﬁltration rate. Adapted from
Martins et al. [27].
APOL1onchromosome22thatprotectagainstalethalform
of African sleeping sickness but are highly associated with an
increased risk of nondiabetic CKD [24] and may explain as
much as 70% of the diﬀerences in the rates of ESRD between
US Whites and African Americans [25]. In addition, genetic
diﬀerences have been known to modulate ethnic responses
to therapeutic agents and may contribute to diﬀerences in
CKD outcomes across racial and ethnic lines [26]. The
understanding of the epidemiologic, genetic, and socio-
cultural nuances of CKD among disadvantaged populations
worldwide will facilitate the development of appropriate
treatment strategies that will optimize the clinical outcomes
in these vulnerable populations.
3. EvaluationandTreatment
The earliest stage of CKD is characterized by the presence
of microalbuminuria and a normal eGFR. This subtle man-
ifestation of CKD has been associated with a 25- to 40-fold
increase in the risk for ESRD and carries comparable risks of
developing CV disease and ESRD as stage 3 CKD [28]. In an
analysis of persons with optimal and high-normal BP, there
was no signiﬁcant diﬀerence in the risk of microalbuminuria
among Whites, but a trend toward increased risk of microal-
buminuria among Mexican Americans (OR 1.16; CI 0.90–
1.51), and a signiﬁcantly increased risk of microalbuminuria
among African Americans (OR 1.30; CI 1.04–1.64) was
observed [29]. The greater risk of proteinuria exhibited by
Table 2: Cardiovascular disease risk factors associated with CKD
progression.
Modiﬁable
High blood pressure
Dyslipidemia (e.g., elevated LDL, decreased HDL)
Diabetes mellitus
Smoking
Overweight and obesity
Atherosclerosis
Coronary artery disease
Congestive heart failure
Unmodiﬁable
Age (≥ 65 years)
Family history of premature CVD
Male gender
Menopause
US racial ethnic minority status (African Americans,
American Indians, and Asian Americans)
Data from [7].
African Americans at any given level of increased BP may
contribute in part to the nearly ﬁvefold greater increase in
the overall incidence of hypertension-related ESRD among
African Americans compared to Whites, as well as the more
than 15 times greater rates of hypertension-related ESRD for4 International Journal of Nephrology
Table 3: Life style modiﬁcations for cardiovascular risk reduction.
Goals Lifestyle Modiﬁcations
Weight loss
Lose weight gradually by making permanent changes in daily diet for the entire family.
Initiate a 10kcal per pound of body weight per day diet.
Set a reasonable weight loss goal (1-2lb/week for ﬁrst 3–6 months).
Dietary goals:
Low fat
Low sodium
High potassium
High calcium
Eat more broiled and steamed foods.
Eat more grains, fresh fruits, and vegetables.
Eat fewer fats and use healthier fats, such as olive oil.
Eat fewer processed foods, fast foods, and fried foods.
Read labels and pay attention to the sodium salt and fat content of foods.
Do not season foods with smoked meats, such as bacon and ham hocks.
If lactose intolerant, try lactose-free milk or yogurt, or drink calcium-fortiﬁed juices, or soy milk.
Physical ﬁtness
Increase physical activity as part of the daily routine: e.g., if currently sedentary, get oﬀ the bus 6
blocks from home or walk in the evening with spouse, friend or group.
Gradually increase time spent at an enjoyable physical activity to 30–45 minutes 3–5days/week.
Stress management Learn stress reduction techniques and coping skills for speciﬁc stressors in the work and/or home
environment. Meditation, Relaxation, Yoga, Biofeedback, others.
Smoking cessation Stop smoking and advocate for a smoke-free environment
Alcohol moderation Drink no more than 2 beers, 1 glass of wine, or 1 shot of hard liquor per day (50% less for women).
Adapted from Martins DS and Norris KC. Hypertension treatment in African-American: Physiology is less important than sociology. Cleveland Clinic Journal
of Medicine. 2004; 71(9) 735-743.
young African-American men between the ages of 20 and 44
compared to their White counterparts [30].
Cardiovascular risk factors (Table 2) and the presence
of CV disease accelerate the progression of CKD and
confer additional risk of mortality [31]. Conversely, all
stages of CKD are associated with an increased risk for
CV death and complications [32]. A substantial portion of
the etiologic suppositions and therapeutic strategy in disad-
vantaged populations revolve around the important role of
the rennin-angiotensin system (RAS) in the modulation of
hypertension and the mediation of the hypertension-related
complications. The documented role of RAS as a facilitator
of the progression of CKD engendered the expectation of an
attenuated risk of hypertension-related end-organ damage
in populations with low-renin hypertension. But contrary to
this expectation, many African Americans with high rates of
sodium sensitivity and low plasma renin levels experience
more severe hypertension-related end-organ complications
such as proteinuria and cardiorenal disease [33]. The disso-
ciation of the circulating RAS from the intrarenal RAS has
been suggested as a probable mechanism for this unusual
experience based on the observation that upregulation of the
intrarenal RAS accompany renal interstitial inﬂammation
and oxidative stress in the kidneys and cardiovascular
tissues of salt-sensitive rats fed a high-salt diet [34]. Despite
the low circulating renin level, RAS blockade reversed
endothelialdysfunction,attenuatedproteinuria,andreduced
renal injury independent of blood pressure changes in
animal models [35], making RAS inhibition a rational
therapeutic strategic option for low renin hypertension in
CKD, particularly in African Americans with CKD where
local RAS upregulation in the kidney could exacerbate both
diabetic and hypertensive CKD [27].
The eﬀectiveness of this therapeutic strategy has been
demonstrated in the large prospective African Ameri-
can Study of Kidney Disease and Hypertension (AASK)
that examined the eﬀects of two levels of blood-pressure
control (standard: ∼135–140/85–90mmHg and intensive:
≤120/80mmHg) and three classes of initial antihypertensive
therapy (Angiotensin Converting Enzyme [ACE] inhibitor,
beta blocker or calcium channel blocker) on the progres-
sion and outcomes of hypertensive renal disease, excluding
individuals with substantial proteinuria (>2.5g per day),
diabetes, or other causes of CKD and established that the
development of ESRD, doubling of serum creatinine, or
death was less frequent in the ACE inhibitor group than
in the beta-blocker or calcium-channel-blocker groups [36].
Although there was no diﬀerence in the progression of CKD
betweenthebloodpressurelevelgroupsintheoriginalstudy,
a subsequent follow-up study demonstrated a potential
beneﬁt of blood pressure less than 130/80mmHg among the
participants with protein to creatinine excretion ratio greater
than 0.22 (hazard ratio, 0.73; P = 0.01) at baseline [37].
4.Secondary Prevention
ThepreventionofCKDhastobepartofacomprehensiveCV
diseasepreventionstrategytobeaﬀordableandcost-eﬀective
particularly among disadvantaged populations. Many of the
risk factors for CV disease are behavioral and modiﬁable
(Table 3). The identiﬁcation and communication of the risk
attributable to health beliefs and behaviors within the con-
text of overall CV disease burden and risk for CKD should
engage and encourage the patient to be proactive in risk
reduction strategies. The inclusion of additional culturally
appropriate healthcare professionals (e.g., a dietitian, phar-
macist, and social worker) and/or family members can be an
eﬀective strategy to facilitate communication and reinforce
recommended therapeutic lifestyle changes. The KDOQI
Clinical Practice Guidelines on Hypertension and Antihy-
pertensive Agents in Chronic Kidney Disease recommend
initial antihypertensive therapy with an ACE inhibitor or anInternational Journal of Nephrology 5
Angiotensin Receptor Blocker (ARB) for patients with CKD,
regardless of ethnicity recognizing that many will require
combination therapy with a diuretic [38]. The evaluation
of response to therapy should include not only checking
that blood pressure is less than the recommended target of
130/80mmHg but assessing complications and monitoring
the change in the level of proteinuria, which is a powerful
predictor of progression of hypertensive kidney disease in
all patients at any given eGFR in all patients [39]. While
the cost eﬀectiveness of screening the general population
with microalbuminuria is debatable, it is generally accepted
as reasonable to target individuals with cardiovascular risk
factors for CKD screening using microalbuminuria.
5. Conclusion
The management of CKD in disadvantaged populations
requires a comprehensive approach and a detailed atten-
tion to the prevailing socioeconomic and cultural factors
that often militate against optimum clinical outcomes in
these vulnerable persons. Lessons learned from racial/ethnic
minorities and socioeconomically disadvantaged persons in
the USA may provide insights into the care of similar
populations globally. It is our recommendation that the
initial evaluation of patients with CKD be broad enough to
uncover nontraditional risk factors for CKD and include a
comprehensive cardiovascular assessment. We reiterate that
the initial therapy for treating hypertension and/or protein-
uria in all patients with CKD comprise RAS inhibition with
diuretic, because this combination appears most eﬀective
to achieve BP control and to confer additional cardiorenal
protection beyond that oﬀered by blood-pressure control
alone. However, the overall treatment decision should be
guided by individual response, coexisting risk factors and
potential cultural/socioeconomic considerations such as
cost of medications and insurance coverage, which aﬀect
adherence to both pharmacologic and nonpharmacologic
interventions.
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